Trishna Goswami
Chief Tech/Sci/R&D Officer at IN8BIO, INC.
Net worth: 8 008 $ as of 30/05/2024
Trishna Goswami active positions
Companies | Position | Start | End |
---|---|---|---|
IN8BIO, INC. | Chief Tech/Sci/R&D Officer | 15/11/2021 | - |
Career history of Trishna Goswami
Former positions of Trishna Goswami
Companies | Position | Start | End |
---|---|---|---|
IMMUNOMEDICS, INC. | Corporate Officer/Principal | 31/05/2018 | 30/11/2021 |
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 30/04/2017 | 31/05/2018 |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | - | - |
Training of Trishna Goswami
Drexel University College of Medicine | Doctorate Degree |
Robert H. Smith School of Business | Masters Business Admin |
Statistics
International
United States | 7 |
Operational
Corporate Officer/Principal | 3 |
Doctorate Degree | 1 |
Masters Business Admin | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
IN8BIO, INC. | Health Technology |
Private companies | 2 |
---|---|
Immunomedics, Inc.
Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Trishna Goswami
- Experience